Atezolizumab

Chemical formula: C₆₄₄₆H₉₉₀₂N₁₇₀₆O₁₉₉₈S₄₂

Therapeutic indications

Atezolizumab is indicated for:

Urothelial carcinoma

Population group: only adults (18 years old or older)

Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):

after prior platinum-containing chemotherapy, or
who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥5%.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Nonsquamous nonsmall cell neoplasm of lung

Population group: only adults (18 years old or older)

Atezolizumab, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR-mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

Atezolizumab, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR-mutant or ALK-positive NSCLC.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Small cell carcinoma of lung

Population group: only adults (18 years old or older)

Atezolizumab, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Early-stage non-small cell lung cancer, EGFR and ALK-negative

Population group: only adults (18 years old or older)

Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks for 1 year

Triple-negative breast cancer with PD-L1 ≥1%

Population group: only adults (18 years old or older)

Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Hepatocellular carcinoma

Population group: only adults (18 years old or older)

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable HCC who have not received prior systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Metastatic non-small cell lung cancer, metastatic, EGFR and ALK-negative

Population group: only adults (18 years old or older)

Atezolizumab as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥50% TC or ≥10% tumour-infiltrating immune cells (IC) and who do not have EGFR-mutant or ALK-positive NSCLC.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Platinum-ineligible non-small cell lung cancer

Population group: only adults (18 years old or older)

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Non-small cell lung cancer, second-line treatment

Population group: only adults (18 years old or older)

Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR-mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks

Contraindications

Atezolizumab is contraindicated in the following cases:

Lactation

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈